Welcome to our dedicated page for Adicet Bio news (Ticker: ACET), a resource for investors and traders seeking the latest updates and insights on Adicet Bio stock.
Adicet Bio, Inc. (Nasdaq: ACET) is a clinical-stage biotechnology company developing allogeneic gamma delta CAR T cell therapies for autoimmune diseases and cancer. The ACET news feed on Stock Titan aggregates company-issued updates, SEC-linked announcements, and other coverage related to Adicet’s clinical programs, capital markets activity, and regulatory interactions.
Investors and followers of Adicet Bio can use this page to review news on its lead program, prulacabtagene leucel (prula-cel, formerly ADI-001), an investigational allogeneic gamma delta CAR T therapy targeting B cells via an anti-CD20 CAR. Company releases have highlighted Phase 1 data in lupus nephritis and systemic lupus erythematosus, enrollment across additional autoimmune indications such as systemic sclerosis, idiopathic inflammatory myopathy, stiff person syndrome, ANCA associated vasculitis and treatment-refractory rheumatoid arthritis, and regulatory designations including Fast Track status for several of these conditions.
The ACET news stream also reflects Adicet’s oncology work, including updates on ADI-212, a next-generation, gene-edited and armored gamma delta CAR T candidate targeting prostate-specific membrane antigen in metastatic castration-resistant prostate cancer. Preclinical data presentations, plans for regulatory filings, and development timelines are typically communicated through press releases and associated 8-K filings.
Beyond clinical and scientific developments, Adicet Bio’s news includes information on registered direct offerings of common stock and pre-funded warrants, reverse stock split decisions, Nasdaq listing status notices, workforce and pipeline prioritization actions, and participation in healthcare conferences. By reviewing this curated ACET news page, readers can follow how Adicet reports progress in its autoimmune and oncology pipelines, how it manages its capital structure, and how key milestones are communicated through official channels.
Adicet Bio, Inc. (Nasdaq: ACET) announced a poster presentation for its allogeneic gamma delta CAR T cell therapy, ADI-002, at the Society for Immunotherapy of Cancer's 36th Annual Meeting, scheduled for November 10-14, 2021. The poster, titled "ADI-002: an IL-15 armored allogeneic 'off-the-shelf' Vδ1 gamma delta CAR T cell therapy for solid tumors targeting glypican-3 (GPC3)," will be presented from November 12-14, 2021. This development emphasizes Adicet's focus on innovative cancer therapies and marks a significant step in its clinical strategy.
Twist Bioscience (NASDAQ: TWST) and Adicet Bio (NASDA: ACET) have announced a collaboration aimed at accelerating the discovery of gamma delta T cell therapies targeting five undisclosed cancer-related antigens. Twist will utilize its proprietary antibody discovery technologies to aid in engineering immune cells with novel chimeric antigen receptors (CARs), enhancing Adicet's pipeline. The agreement includes an upfront technology licensing fee, clinical and regulatory milestones, and product royalties, emphasizing the partnership's potential in advancing T cell therapies for cancer treatment.
Adicet Bio (Nasdaq: ACET) has partnered with Twist Bioscience to enhance the development of gamma delta T cell therapies targeting five undisclosed cancer markers. This collaboration aims to utilize Twist’s advanced antibody discovery technologies to engineer immune cells equipped with human CARs and TCRs, potentially improving tumor cell recognition and eradication. Twist will receive an upfront technology license fee, alongside milestone payments and royalties from successful products arising from the partnership. Both companies express optimism about accelerating treatment options for cancer patients.
Adicet Bio, Inc. (Nasdaq: ACET) announced its participation in two virtual investor conferences in September 2021. The first is the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, where attendees can access a recorded presentation starting September 13 at 7:00 AM ET. The second event is the 2021 Cantor Virtual Global Healthcare Conference, featuring a fireside chat by CEO Chen Schor on September 27 at 10:00 AM ET. Live and archived audio webcasts will be available on Adicet Bio’s investor website.
Adicet Bio (Nasdaq: ACET) announced its Q2 2021 results, highlighting operational achievements and progress in its lead asset, ADI-001, for Non-Hodgkin's Lymphoma. The company expects to report interim data by 2021's end and has added a scientific advisory board to support its pipeline. Financially, R&D expenses rose to $10.6M, while G&A expenses decreased to $5.0M. The net loss was $10.9M, with a cash position of $208.7M expected to fund operations into mid-2023. Adicet's addition to the Russell 2000 Index could enhance investor visibility.
Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology firm focused on allogeneic gamma delta T cell therapies, announced participation in three virtual investor conferences in August 2021. Key highlights include a fireside chat by CEO Chen Schor at the BTIG Virtual Biotechnology Conference on August 9 at 9:00 AM ET and a panel discussion on August 10 during the Wedbush PacGrow Healthcare Conference, as well as another fireside chat on August 11 at the Canaccord Genuity Annual Growth Conference. A webcast will be available on their investor website.
Adicet Bio (Nasdaq: ACET) announced the formation of a Scientific Advisory Board (SAB) on July 15, 2021. This board comprises distinguished experts in T cell biology, immunology, and oncology, who will provide strategic guidance for advancing Adicet’s lead asset, ADI-001, and its gamma delta T cell therapies. Key members include renowned doctors such as Alice Bertaina, Marco Davila, and Michael Kalos. The new board is expected to enhance the development of innovative cancer treatments, boosting Adicet's potential in the biotechnology sector.
Adicet Bio, Inc. (Nasdaq: ACET) announced its addition to the Russell 2000 Index, effective June 28, 2021. This inclusion reflects the significant progress the company has made in developing allogeneic gamma delta T cell therapies for cancer treatment. CEO Chen Schor expressed optimism that this recognition will enhance visibility for its gamma delta T cell product pipeline. Adicet is expected to release interim clinical data from its lead candidate ADI-001 later this year. The Russell Indexes are utilized widely by institutional investors, managing approximately $10.6 trillion in assets.
Adicet Bio, a biotechnology firm focused on innovative gamma delta T cell therapies, announced participation in two virtual investor conferences. The first is the UBS Global Healthcare Virtual Conference from May 24-26, where CEO Chen Schor will present on May 26 at 7:00 AM ET. The second event is the JMP Securities Life Sciences Conference on June 16-17, featuring a fireside chat with Schor on June 16 at 3:00 PM ET. Live webcasts will be available on their website, with replays accessible for 30 days post-event.
Adicet Bio (Nasdaq: ACET) reported a productive Q1 2021, highlighted by the successful $143.8 million capital raise and the initiation of a Phase 1 trial for ADI-001, targeting B Cell Non-Hodgkin's Lymphoma (NHL). The trial is positioned as the first allogeneic CAR gamma-delta T cell therapy to enter human trials, with interim data expected by late 2021. Despite increased R&D and G&A expenses totaling $17.3 million, the company holds $223.4 million in cash and marketable securities, providing a strong financial foundation through mid-2023.